CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 45.744
AS - Asia 18.783
EU - Europa 18.112
SA - Sud America 2.758
AF - Africa 385
Continente sconosciuto - Info sul continente non disponibili 385
OC - Oceania 44
Totale 86.211
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 44.939
GB - Regno Unito 5.587
SG - Singapore 5.426
CN - Cina 5.168
IT - Italia 4.143
HK - Hong Kong 2.294
BR - Brasile 2.113
VN - Vietnam 1.752
SE - Svezia 1.510
DE - Germania 1.306
BD - Bangladesh 1.227
UA - Ucraina 1.121
FI - Finlandia 1.100
IE - Irlanda 930
TR - Turchia 769
RU - Federazione Russa 656
FR - Francia 632
KR - Corea 462
IN - India 427
BG - Bulgaria 397
CA - Canada 389
ID - Indonesia 245
AR - Argentina 207
MX - Messico 172
IQ - Iraq 139
JP - Giappone 132
NL - Olanda 123
EC - Ecuador 99
ZA - Sudafrica 97
PL - Polonia 93
AE - Emirati Arabi Uniti 91
CO - Colombia 90
ES - Italia 88
PK - Pakistan 81
BE - Belgio 79
VE - Venezuela 70
PH - Filippine 63
MY - Malesia 62
CL - Cile 61
UZ - Uzbekistan 54
SA - Arabia Saudita 52
JM - Giamaica 49
PY - Paraguay 48
MA - Marocco 47
CR - Costa Rica 45
LT - Lituania 43
AU - Australia 42
EG - Egitto 38
NP - Nepal 37
CZ - Repubblica Ceca 36
KE - Kenya 35
AT - Austria 34
JO - Giordania 33
HN - Honduras 32
TH - Thailandia 31
TN - Tunisia 29
AL - Albania 27
IR - Iran 27
AZ - Azerbaigian 25
ET - Etiopia 25
HU - Ungheria 25
UY - Uruguay 25
TW - Taiwan 24
RO - Romania 23
DZ - Algeria 22
RS - Serbia 22
BO - Bolivia 21
DO - Repubblica Dominicana 21
PE - Perù 21
CH - Svizzera 20
IL - Israele 19
PT - Portogallo 18
KZ - Kazakistan 17
LB - Libano 17
OM - Oman 17
TT - Trinidad e Tobago 17
GR - Grecia 16
NG - Nigeria 16
SN - Senegal 14
NI - Nicaragua 13
SI - Slovenia 13
SK - Slovacchia (Repubblica Slovacca) 12
BH - Bahrain 11
GT - Guatemala 11
CI - Costa d'Avorio 10
EU - Europa 10
KG - Kirghizistan 10
PA - Panama 10
PR - Porto Rico 10
QA - Qatar 10
SY - Repubblica araba siriana 10
MD - Moldavia 9
PS - Palestinian Territory 9
AM - Armenia 8
BW - Botswana 8
AO - Angola 7
BB - Barbados 7
DK - Danimarca 7
MK - Macedonia 7
NO - Norvegia 7
Totale 85.703
Salva come PNG Salva come JPEG
Città #
Fairfield 4.174
Ashburn 3.993
Southend 3.802
Singapore 3.513
Santa Clara 3.102
Woodbridge 3.075
Houston 2.634
Jacksonville 2.296
Hong Kong 2.261
Chandler 2.036
Ann Arbor 1.737
Dearborn 1.572
Seattle 1.549
Wilmington 1.529
Hefei 1.526
Cambridge 1.377
San Jose 1.369
Council Bluffs 1.060
Beijing 1.032
London 942
Dublin 924
Nyköping 827
Los Angeles 760
Helsinki 711
Modena 641
Chicago 638
The Dalles 636
Ho Chi Minh City 587
New York 571
Milan 472
Princeton 444
San Diego 433
Seoul 429
Hanoi 396
Sofia 381
Eugene 379
Izmir 364
Columbus 331
Lauterbourg 319
Buffalo 301
Salt Lake City 227
Shanghai 213
Rome 210
Des Moines 207
Moscow 203
Dallas 198
São Paulo 194
Boardman 188
Jakarta 150
Falls Church 143
Munich 141
Phoenix 141
Frankfurt am Main 122
Elk Grove Village 117
Tampa 113
Bologna 106
Naples 96
Norwalk 94
Tokyo 92
Orem 87
Guangzhou 85
Da Nang 80
Atlanta 77
Toronto 76
Brussels 71
Haiphong 71
Denver 69
Turin 68
Florence 67
Miano 66
Lancaster 64
Mexico City 63
Chennai 62
Warsaw 62
Redwood City 58
Rio de Janeiro 57
Brooklyn 56
Dong Ket 54
Sterling 54
Fremont 53
Belo Horizonte 51
Nanjing 51
Porto Alegre 51
Bremen 49
Kunming 49
Montreal 49
Bari 47
Redondo Beach 47
Philadelphia 46
Falkenstein 45
North Bergen 45
Tashkent 45
Brasília 44
Miami 44
Verona 44
Boston 43
Baghdad 41
Mumbai 41
Palermo 39
Kilburn 38
Totale 60.387
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.175
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 499
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 451
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 450
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 435
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 435
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 432
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 426
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 423
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 419
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 413
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 413
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 405
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 404
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 399
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 398
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 395
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 392
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 392
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 391
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 389
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 388
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 384
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 384
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 377
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 368
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 368
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 364
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 363
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 361
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 358
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 357
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 352
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 349
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 346
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 345
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 341
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 339
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 338
Achievements and unmet needs in the management of advanced ovarian cancer 335
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 333
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 333
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 330
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 330
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 328
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 327
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 326
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 326
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 325
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 323
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 321
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 320
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 316
Immune characterization of breast cancer metastases: prognostic implications. 315
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 314
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 313
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 313
5-Fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer 312
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 311
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 306
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 304
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 301
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 300
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 300
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 299
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 295
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 295
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 290
Significance of lymph node sampling in epithelial carcinoma of the ovary. 287
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 284
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 284
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 284
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 281
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 280
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 278
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 277
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 275
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 275
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 275
The curability of breast cancer and the treatment of advanced disease 274
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 273
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 273
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 271
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 270
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 270
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 269
Device for cell culture 266
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. 265
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 264
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 263
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 263
Biomarkers predicting clinical benefit: fact or fiction? 259
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 257
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 257
Biomarker expression and survival after primary chemotherapy for breast cancer. 257
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 256
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 256
A phase II study with danazol in metastatic breast cancer. 255
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 253
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 253
Totale 33.763
Salva come PNG Salva come JPEG
Categoria #
all - tutte 326.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 326.963
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.200 0 0 783 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/202511.504 362 159 183 872 2.139 1.812 493 761 1.480 780 1.022 1.441
2025/202625.948 1.329 1.003 2.221 3.016 3.369 2.034 2.813 1.440 2.168 2.625 2.172 1.758
2026/20273.686 1.011 1.759 916 0 0 0 0 0 0 0 0 0
Totale 86.211